This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutPathogen CoveragePatient Risk FactorsAntimicrobial Subscription Model PilotDosingDosingDosingPreparation GuideShelf Life and StorageEfficacy & SafetyEfficacy & SafetyMechanism of ActionREPROVE Phase III trial(HAP/VAP)RECLAIM Phase III trial(cIAI)RECAPTURE Phase III trial(cUTI)REPRISE Phase III trial(cIAI and cUTI)Safety and TolerabilityEfficacy and Safety Data for Paediatric PatientsSupport & ResourcesSupport & ResourcesAMS ResourcesSepsisWebinars (Live and On-demand)KOL Videos - ZaviceftaKOL Videos - Gram-negativeKOL Videos - Clinical experienceVideosMaterials

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

For patients requiring treatment of infections due to resistant, aerobic Gram-negative bacteriaZAVICEFTA® for the treatment of patients with suspected or documented Enterobacteriaceae and P. aeruginosa infection with resistance to ESBLs, KPC & OXA-48 carbapenemases and AmpC enzymes1–4 Ceftazidime

A broad spectrum, third-generation antipseudomonal cephalosporin with a well characterized efficacy and tolerability profile1,2.

Avibactam

A β-lactamase inhibitor, which allows ceftazidime to maintain activity in presence of certain resistance mechanisms1,2.

The combination of ceftazidime and avibactam provides broad spectrum Gram-negative pathogen coverage Watch animation on Zavicefta mechanism of action Loading

Gram-negative pathogen coverage by indication5-9*

Scroll left to view table
Content cIAIs cUTIs HAP/VAP
Citrobacter freundii Helix image

Enterobacter cloacae ​​​​​​​Helix image ​​​​​​​Helix image ​​​​​​​Helix image
Escherichia coli ​​​​​​​Helix image ​​​​​​​Helix image ​​​​​​​Helix image
Klebsiella oxytoca Helix image​​​​​​​

Klebsiella pneumoniae Helix image​​​​​​​​​​​​​​​​​​​​​ Helix image​​​​​​​ Helix image​​​​​​​
Proteus mirabilis
Helix image​​​​​​​ Helix image​​​​​​​
Pseudomonas aeruginosa Helix image Helix image​​​​​​​ Helix image​​​​​​​
Serratia marcescens

Helix image​​​​​​​

*In vitro data indicate that the following species are not susceptible to ZAVICEFTA: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), anaerobes, Enterococcus spp., Stenotrophomonas maltophilia and Acinetobacter spp.

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes10

Read more about patient risk factors in HAP/VAP,cUTI and cIAI

Abbreviations

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; CrCl, creatinine clearance; ELF, epithelial lining fluid; AMR, Antimicrobial Resistance; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing;

Prescribing Information

Click here for ZAVICEFTA® (ceftazidime and avibactam) Prescribing Information

Click here for MERONEM® Prescribing Information

Click here for TAZOCIN® (piperacillin sodium, tazobactam sodium) Prescribing Information

Click here for AMIKACIN (amikacin sulfate) Prescribing Information

Click here for TOBRAMYCIN (tobramycin) Prescribing Information

References

ZAVICEFTA. Summary of Product CharacteristicsLiscio JL, et al. Int J Antimicrob Agents 2015;46:266–71Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9Mazuski JE, et al. Surg Infect 2017;18:1–76Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65Miller BM, et al. Am J Infect Control 2016;44:134–7
De Waele J, et al. Intensive Care Med 2018;44:189–96
Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23Harris AD, et al. Emerg Infect Dis 2007;13:1144–9Bonine NG, et al. Am J Med Sci 2019;357:102–10
PP-ZVA-GBR-1714. February 2023
Access case studies and videosLearn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials. View tolerability profileLoading Alex Soriano

Infectious Disease Physician at Hospital Clinic in Barcelona, Spain, summarises key ZAVICEFTA data against other β-lactam/β-lactamase inhibitor combinations. He discusses ZAVICEFTA’s in vitro activity and broad-spectrum coverage against MDR P. aeruginosa and Enterobacteriaceae (including Klebsiella pneumoniaeEscherichia coli and ESBL-producing strains).

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​